Suppr超能文献

[通过一种新型夹心式荧光偏振筛选测定法鉴定严重急性呼吸综合征冠状病毒2主要蛋白酶抑制剂]

[Identifying SARS-CoV-2 main protease inhibitors by a novel sandwich-like fluorescence polarization screening assay].

作者信息

Yan Haohao, Yan Gangan, Qi Haiyan, Liu Zhicheng, Liu Xiaoli, Liu Xiaoping, Li Ni, Chen Yunyu

机构信息

Institute for Drug Screening and Evaluation, Wannan Medical College, Wuhu 241002, Anhui, China.

State Key Laboratory of Bioactive Substances and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

出版信息

Sheng Wu Gong Cheng Xue Bao. 2022 Jun 25;38(6):2352-2364. doi: 10.13345/j.cjb.210949.

Abstract

SARS-CoV-2 main protease (Mpro) is responsible for polyprotein cleavage to release non-structural proteins (nsps) for viral genomic RNA replication, and its homologues are absent in human cells. Therefore, Mpro has been regarded as one of the ideal drug targets for the treatment of coronavirus disease 2019 (COVID-19). In this study, we first combined the fluorescence polarization (FP) technique with biotin-avidin system (BAS) to develop a novel sandwich-like FP screening assay for quick discovery of SARS-CoV-2 Mpro inhibitors from a natural product library. With this screening assay, anacardic acid (AA) and 1, 2, 3, 4, 6--pentagalloylglucose (PGG) were found to be the competitive inhibitor and mixed-type inhibitor targeting Mpro, respectively. Importantly, our results showed that the majority of the reported Mpro inhibitors are promiscuous cysteine inhibitors that are not specific to Mpro. In summary, this novel sandwich-like FP screening assay is simple, sensitive, and robust, which is ideal for large-scale screening. Natural products AA and PGG will be the promising lead compounds for generating more potent antiviral agents targeting Mpro, and the stringent hit validation at the early stage of drug discovery is urgently needed.

摘要

严重急性呼吸综合征冠状病毒2型主要蛋白酶(Mpro)负责切割多聚蛋白以释放非结构蛋白(nsps)用于病毒基因组RNA复制,而其同源物在人类细胞中不存在。因此,Mpro被视为治疗2019冠状病毒病(COVID-19)的理想药物靶点之一。在本研究中,我们首先将荧光偏振(FP)技术与生物素-抗生物素蛋白系统(BAS)相结合,开发了一种新型的类夹心FP筛选测定法,用于从天然产物库中快速发现严重急性呼吸综合征冠状病毒2型Mpro抑制剂。通过这种筛选测定法,发现没食子酸(AA)和1,2,3,4,6-五没食子酰葡萄糖(PGG)分别是靶向Mpro的竞争性抑制剂和混合型抑制剂。重要的是,我们的结果表明,大多数已报道的Mpro抑制剂是不特异于Mpro的混杂型半胱氨酸抑制剂。总之,这种新型的类夹心FP筛选测定法简单、灵敏且稳健,非常适合大规模筛选。天然产物AA和PGG将是生成更有效的靶向Mpro抗病毒药物的有前景的先导化合物,并且在药物发现的早期阶段迫切需要严格的命中验证。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验